miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference
28 Maio 2019 - 5:30PM
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage
biopharmaceutical company developing proprietary RNA-targeted
therapies with a specific focus on microRNAs, announced today that
William S. Marshall, Ph.D., President and Chief Executive Officer,
will provide a corporate overview at the Jefferies 2019
Global Healthcare Conference, taking place June 4-7 in New
York City.
Jefferies 2019 Global Healthcare
Conference |
Date: |
Tuesday, June
4th |
Time: |
9:00am Eastern Time |
Webcast: |
http://wsw.com/webcast/jeff118/mgen/ |
The presentation will be webcast live and may
also be accessed by visiting the "Investors & Media" section of
the Company’s web site at www.miragen.com. A replay of the
webcast will be available for 90 days after the event.
About miRagen Therapeutics,
Inc.
miRagen Therapeutics, Inc. is a clinical-stage
biopharmaceutical company discovering and developing proprietary
RNA-targeted therapies with a specific focus on microRNAs and their
role in diseases where there is a high unmet medical need. miRagen
has three clinical stage product candidates, cobomarsen, remlarsen,
and MRG-110. miRagen’s clinical product candidate for the treatment
of certain cancers, cobomarsen, is an inhibitor of microRNA-155,
which is found at abnormally high levels in malignant cells of
several blood cancers. miRagen’s clinical product candidate for the
treatment of pathological fibrosis, remlarsen, is a replacement for
microRNA-29, which is found at abnormally low levels in a number of
pathological fibrotic conditions, including cutaneous, cardiac,
renal, hepatic, pulmonary and ocular fibrosis, as well as in
systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is being
developed under a license and collaboration agreement with Servier
for the treatment of heart failure and other ischemic disease. In
addition to these programs, miRagen is developing a pipeline of
preclinical product candidates. The goal of miRagen’s translational
medicine strategy is to progress rapidly to first-in-human studies
once it has established the pharmacokinetics, pharmacodynamic,
safety, and manufacturability of the product candidate in
preclinical studies. For more information, please visit
www.miragen.com.
For information on clinical trials please visit
www.clinicaltrials.gov.
Investor/Media Contact: Adam Levy, Chief
Business Officer(720) 407-4595alevy@miragen.com
Miragen Therapeutics (NASDAQ:MGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Miragen Therapeutics (NASDAQ:MGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024